Post-earnings recap
Reported
Thu, Feb 15, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that while Alnylam Pharmaceuticals exceeded expectations on EPS, the stock reacted negatively, dropping 10.19%. This decline may reflect investor concerns over the lack of revenue data and the absence of future guidance. The management's defensive tone suggests they are facing challenges that could impact growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.77 | N/A | +35.99% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions and the impact on future performance. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.